|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM060608544 |
| 003 |
DE-627 |
| 005 |
20231221214118.0 |
| 007 |
tu |
| 008 |
231221s1984 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0202.xml
|
| 035 |
|
|
|a (DE-627)NLM060608544
|
| 035 |
|
|
|a (NLM)6083719
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Sekine, H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Combination chemotherapy with bleomycin, vinca alkaloid and cisplatin (BVP) for advanced urothelial cancer
|
| 264 |
|
1 |
|c 1984
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.02.1985
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Since October 1979, 18 patients with metastatic urothelial cancer have been treated with combination chemotherapy of bleomycin (5-10 mg/day administered on days 1 to 7), vinca alkaloid (vinblastine 5-10 mg/day or vincristine 1 mg/sqm on days 8 and 9) and CDDP (60 mg/sqm on day 10). CR was achieved in 3 of the 18 patients and PR in 6 patients. Over-all, the response rate was 50%. Among 3 patients who achieved CR, 2 patients are still free of disease for 31 months and for 28 months, and the other is alive with cancer for 26 months. The 2-year survival rate was 58% in responders (CR + PR) and 0% in nonresponders. (p less than 0.005). In many cases, the response was observed after the first or second course of BVP therapy, and there was a relatively good response in patients with lymphnode metastasis alone. The treatment was tolerated well and common toxic effects were nausea, vomiting of moderate to severe degree (100%), myelosuppression (50%) and mild nephrotoxicity (22%). As to the choice of vinca alkaloids, vincristine seemed to be the treatment of choice because it was less toxic than vinblastine and was almost equally effective
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Bleomycin
|2 NLM
|
| 650 |
|
7 |
|a 11056-06-7
|2 NLM
|
| 650 |
|
7 |
|a Vinblastine
|2 NLM
|
| 650 |
|
7 |
|a 5V9KLZ54CY
|2 NLM
|
| 650 |
|
7 |
|a Prednisone
|2 NLM
|
| 650 |
|
7 |
|a VB0R961HZT
|2 NLM
|
| 700 |
1 |
|
|a Fukui, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamada, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takeuchi, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tachibana, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yokokawa, M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 30(1984), 8 vom: 15. Aug., Seite 1095-9
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:30
|g year:1984
|g number:8
|g day:15
|g month:08
|g pages:1095-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 30
|j 1984
|e 8
|b 15
|c 08
|h 1095-9
|